Search alternatives:
linear decrease » linear increase (Expand Search)
system decrease » step decrease (Expand Search)
ann decrease » nn decrease (Expand Search), a decrease (Expand Search), gain decreased (Expand Search)
_ system » _ systems (Expand Search), _ systemic (Expand Search)
_ ann » _ any (Expand Search), _ anc (Expand Search)
Showing 1 - 20 results of 13,118 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ((( _ system decrease ) OR ( _ ann decrease ))))', query time: 0.49s Refine Results
  1. 1
    The linearly decreasing convergence factor a.

    The linearly decreasing convergence factor a. by Junhao Wei (6816803)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Baseline patient characteristics.

    Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Effects of s-ketamine and midazolam on respiratory parameters.

    Effects of s-ketamine and midazolam on respiratory parameters. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Flow chart of the study participants.

    Flow chart of the study participants. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    ANN architecture.

    ANN architecture. by Abdelfattah Dani (22226715)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Results of dose linearity.

    Results of dose linearity. by Masakazu Tsujimoto (22339504)

    Published 2025
    Save to List
    Saved in:
  8. 8
    ANN architecture and configuration.

    ANN architecture and configuration. by Abdelfattah Dani (22226715)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital

    S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital by Sonsawan Sangprasert (22772538)

    Published 2025
    “…S2 File - <p>Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital</p>…”
    Save to List
    Saved in:
  10. 10
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: